My name is Hardy Rideout, and I am the CSO of Anacalypsis Therapeutics, based in Athens Greece. The focus of our work is the discovery of novel disease-modifying therapeutics to offer people suffering from neurodegenerative diseases such as Parkinson's disease. We are also developing in parallel, a suite of biomarker tools to help boost the impact of our therapeutics by improving patient screening and selection, as well as more sensitive tools to track the progression of this disease and treatment effectiveness. Our approach of linking therapeutics development and biomarkers has the potential to transform the way in which Parkinson's disease is treated. We are seeking Seed financing to advance three parallel therapeutic programmes, in addition to their companion biomarker tools.